Establishment Labs (NASDAQ:ESTA) Hits New 12-Month High – Here’s Why

Establishment Labs Holdings Inc. (NASDAQ:ESTA) hit a new 52-week high during trading on Wednesday . The company traded as high as $89.36 and last traded at $89.0290, with a volume of 117060 shares trading hands. The stock had previously closed at $87.01.

Analyst Upgrades and Downgrades

ESTA has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. BTIG Research lifted their target price on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Stephens upped their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, Needham & Company LLC raised their price objective on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $87.14.

Establishment Labs Stock Performance

The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. The stock has a market cap of $2.59 billion, a PE ratio of -59.24 and a beta of 1.11. The business has a 50 day moving average price of $72.24 and a two-hundred day moving average price of $69.98.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm’s quarterly revenue was up 44.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.70) earnings per share. As a group, equities research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Insider Activity at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the sale, the director directly owned 927,504 shares in the company, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 292,500 shares of company stock worth $20,591,021 over the last ninety days. Corporate insiders own 9.99% of the company’s stock.

Institutional Investors Weigh In On Establishment Labs

Institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its stake in shares of Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after buying an additional 438,206 shares during the period. Viking Global Investors LP bought a new stake in Establishment Labs in the second quarter valued at $14,669,000. Bamco Inc. NY increased its position in Establishment Labs by 30.2% during the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after purchasing an additional 274,287 shares during the period. Soleus Capital Management L.P. purchased a new position in Establishment Labs during the 2nd quarter valued at $9,050,000. Finally, Summit Partners Public Asset Management LLC raised its holdings in Establishment Labs by 87.1% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock worth $17,632,000 after purchasing an additional 200,255 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.